Bioxodes is a dynamic biotech start-up specialized in the development of novel therapeutics using molecules derived from nature to prevent thrombosis and inflammatory processes

NEWS : Bioxodes obtains authorization to launch phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers.

Read the blog article written by BioVox about our antithombotic candidate, Ir-CPI.